X0306 4 2021-10-19 false 0001531048 Inari Medical, Inc. NARI 0001806431 Hykes Andrew C/O INARI MEDICAL, INC. 6001 OAK CANYON, SUITE 100 IRVINE CA 92618 false true false false Chief Operating Officer Common Stock 2021-10-19 4 S false 1180.00 85.4675 D 167647.00 D Common Stock 2021-10-19 4 S false 1812.00 86.9312 D 165835.00 D Common Stock 2021-10-19 4 S false 5508.00 88.4032 D 160327.00 D Common Stock 2021-10-19 4 S false 500.00 89.164 D 159827.00 D Common Stock 1550.00 I By Child 3 Common Stock1 1550.00 I By Child 2 Common Stock 1550.00 I By Child 1 Common Stock 1000.00 I By Spouse The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. This transaction was executed in multiple trades at prices ranging from $85.07 to $85.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $86.61 to $87.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $87.89 to $88.86. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $88.89 to $89.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. /s/ Angela Ahmad, attorney-in-fact for Andrew Hykes 2021-10-20